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Abstract
Background: Dysfunctional lipid metabolism is a hallmark of obesity and insulin resistance and a risk factor for various
cardiovascular and metabolic complications. In addition to the well known increase in plasma triglycerides and free fatty
acids, recent work in humans and rodents has shown that obesity is associated with elevations in the bioactive class of
sphingolipids known as ceramides. However, in obesity little is known about the plasma concentrations of sphinogsine-1-
phosphate (S1P), the breakdown product of ceramide, which is an important signaling molecule in mammalian biology.
Therefore, the purpose of this study was to examine the impact of obesity on circulating S1P concentration and its
relationship with markers of glucose metabolism and insulin sensitivity.
Methodology/Principal Findings: Plasma S1P levels were determined in high-fat diet (HFD)-induced and genetically obese
(ob/ob) mice along with obese humans. Circulating S1P was elevated in both obese mouse models and in obese humans
compared with lean healthy controls. Furthermore, in humans, plasma S1P positively correlated with total body fat
percentage, body mass index (BMI), waist circumference, fasting insulin, HOMA-IR, HbA1c (%), total and LDL cholesterol. In
addition, fasting increased plasma S1P levels in lean healthy mice.
Conclusion: We show that elevations in plasma S1P are a feature of both human and rodent obesity and correlate with
metabolic abnormalities such as adiposity and insulin resistance.
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Introduction
The global prevalence of obesity is growing at an alarming rate.
This is of particular concern especially given that obesity is
associated with an array of metabolic complications, including
insulin resistance and type 2 diabetes mellitus [1]. In addition to
defects in glucose metabolism, these conditions are also closely
associated with dyslipidaemia, evident by an increase in circulating
lipids including triglycerides and free fatty acids [2]. The
dyslipidaemia is thought to arise from an oversupply of both
exogenous dietary chylomicron derived lipids along with endog-
enously synthesized lipids such as those released from the liver (ie.
cholesterol, triacylglycerol) and adipose tissue (ie. free fatty acids).
Traditionally, elevations of these commonly measured circulating
lipids have been used clinically to assess the risk of metabolic and
heart disease [3]. While this approach has been useful, recently
there has been an emergence of research attempting to identify
other circulating lipid species that may prove to be more accurate
biomarkers of disease onset and progression [4–7]. In this regard,
circulating sphingolipids have emerged as potential biomarkers
and mediators of disease development [8–12].
Sphingolipids are a complex class of lipids that play important
structural, signaling and cell recognition roles [13] and have been
implicated in the development of metabolic diseases including
insulin resistance and type 2 diabetes [4,8,9,12,14,15]. Plasma
ceramide levels are elevated in type 2 diabetic patients [8,14] and
are inversely associated with measures of insulin sensitivity [8].
Moreover, we recently demonstrated that circulating ceramide is
taken up and deposited in skeletal muscle promoting the
development of insulin resistance [14]. While we are beginning
to develop an appreciation of the importance of circulating
ceramide [4,8,9,12,14,15], the role of other sphingolipids, in
particular sphingosine-1-phosphate (S1P), has received little
attention with respect to its relationship with obesity, insulin
resistance and type 2 diabetes. S1P is a breakdown product of
ceramide metabolism and circulates in mammals at high levels
(.200 nM), whereas in the interstitial fluid the levels are very low,
thus creating an S1P compartment gradient [16,17]. It is thought
that both haematopoietic and vascular endothelial cells are the
major contributors to the plasma S1P pool [16,18], with
approximately 65% of the plasma S1P being bound to lipopro-
teins, of which ,50% is associated with HDL, while the
remainder is bound to albumin [17,19]. S1P has effects on many
biological processes, with some of the most well characterized
effects being on the immune and vascular systems, particularly in
the process of inflammation [13,20]. S1P has both physiological
and pathophysiological roles, regulating cell signaling, prolifera-
tion, migration, survival, differentiation and metabolism, and its
effects can be traced to essentially all organ systems [13,20].
Interestingly, plasma S1P levels are increased in the genetically
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e72449
obese ob/ob mouse [12] and in rodent models of type 1 diabetes
[21]. Furthermore, in vitro studies using C2C12 myoblasts have
shown that S1P can stimulate basal glucose uptake by trans-
phosphorylation of the insulin receptor [22], while in rat primary
adipocytes S1P has been shown to stimulate lipolysis [23]. These
findings suggest that S1P levels may either effect or be affected by
the metabolic status of the individual. However, there is currently
little known about the circulating levels of S1P in obesity and
insulin resistance. Therefore, the purpose of this study was to
examine the impact of obesity on circulating S1P levels and to
determine whether there is a relationship between its concentra-
tions and clinical indices of metabolic dysfunction.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Monash
University Animal Research Platform Animal Ethics Committee
and were in accordance with the National Health and Medical
Research Council of Australia Guidelines on Animal Experimen-
tation. The human study was approved by The Alfred Human
Research Ethics Committee, performed in accordance with the
Declaration of Helsinki (fifth revision, 2000) and each participant
provided written informed consent.
Animal Studies
Male C57BL/6 mice at 8 weeks of age were fed a control chow
(,9% energy as fat, Barastok Rat & Mouse, Ridley AgriProducts,
Melbourne, Australia) or high-fat diet (,42% energy as fat,
Specialty Feeds SF4-001, Glen Forrest, WA, Australia) for 6
weeks. Genetically obese male ob/ob mice on a pure C57BL/6
background and lean littermate controls maintained on a standard
chow diet were studied at 20 weeks of age. Metabolic character-
istics of the mice are presented in Table 1 and 2. Blood collection
was performed after a 5 h fast via the tail vein. For the fed and
fasting study, 8 week old male C57BL/6 mice on a chow diet had
tail vein blood collected at 06:00 (fed condition) after which food
was removed until 18:00 (fasted state) when blood was again
collected for biochemical analysis.
Human Studies
Fifteen lean and 10 obese (BMI .30 kg/m2) otherwise healthy
young men were studied. These individuals were recruited as part
of a larger study which has recently been published [24]. The
characteristics of all participants are presented in Table 3.
Participants arrived at the laboratory following an overnight fast
and the physical characteristics (height, weight, waist circumfer-
ence brachial blood pressure) of each subject were measured. An
18-G cannula was inserted into an antecubital vein and a venous
blood sample was obtained for measurement of HbA1c, blood
glucose, plasma insulin and lipids. An oral glucose tolerance test
(OGTT) was then performed. Subjects ingested a 75 g glucose
load and blood was sampled at 60 and 120 min for the
measurement of blood glucose. Body composition was measured
using dual energy x-ray absorptiometry (DEXA).
Biochemical Analyses
Venous blood samples obtained from the human subjects were
centrifuged and plasma immediately frozen. Plasma was subse-
Table 1. Metabolic characteristics of the chow and high-fat
diet fed mice.
Chow HFD P-Value
Sample size (N) 13 14 N/A
Body mass (g) 31.160.9 39.761.2 P,0.001
Lean mass (g) 26.860.9 26.860.6 P = 0.94
Fat mass (g) 3.160.4 11.960.8 P,0.001
Fasting blood glucose (mmol/l) 10.360.4 12.160.5 P = 0.009
Fasting plasma insulin (pmol/l) 90.066.1 624.1688.7 P,0.001
Plasma NEFA (mmol/l) 0.5560.07 0.5860.02 P = 0.71
Plasma triglyceride (mmol/l) 0.4060.03 0.5560.02 P,0.001
Data are mean 6 SEM. HFD; high-fat diet.
doi:10.1371/journal.pone.0072449.t001
Table 2. Metabolic characteristics of the lean and ob/ob mice.
Lean ob/ob P-Value
Sample size (N) 6 8 N/A
Body mass (g) 29.460.7 61.060.9 P,0.001
Subcutaneous fat pad (g) 0.560.1 4.560.7 P,0.001
Gonadal fat pad (g) 1.060.3 4.160.5 P,0.001
Fasting blood glucose (mmol/l) 6.760.3 10.161.2 P = 0.036
Data are mean 6 SEM.
doi:10.1371/journal.pone.0072449.t002
Table 3. Participant characteristics.
Lean Obese P-Value
Sample size (N) 15 10 N/A
Age (yr) 25.261.0 27.561.3 P = 0.073
Body mass (kg) 67.662.2 116.264.8 P,0.001
Height (cm) 176.562.4 177.561.8 P = 0.72
BMI (kg.m22) 21.760.5 36.961.41 P,0.001
Waist circumference (cm) 78.461.4 114.562.6 P,0.001
Body fat (%) 18.061.6 44.861.6 P,0.001
Fasting blood glucose (mmol/l) 5.160.1 5.160.1 P = 0.99
60 min OGTT blood glucose
(mmol/l)
5.960.4 7.360.5 P = 0.018
120 min OGTT blood glucose
(mmol/l)
4.660.3 5.960.4 P = 0.009
Fasting plasma insulin (pmol/l) 38.666.7 91.5613.4 P,0.001
HOMA-IR 1.360.3 3.060.5 P = 0.001
HbA1c (%) 5.560.1 5.560.1 P = 0.56
Systolic blood pressure (mm Hg) 11763 11962 P = 0.276
Diastolic blood pressure (mm Hg) 73.262.6 70.961.9 P = 0.99
Mean arterial pressure (mm Hg) 86.862.8 86.561.9 P = 0.572
Total cholesterol (mmol/l) 4.360.2 4.760.1 P = 0.13
LDL cholesterol (mmol/l) 2.660.2 3.160.2 P = 0.059
HDL cholesterol (mmol/l) 1.360.1 1.060.1 P = 0.015
Plasma triglyceride (mmol/l) 0.860.1 1.360.2 P = 0.041
Plasma NEFA (mmol/l) 0.3060.03 0.4360.05 P = 0.048
Plasma glycerol (mmol/l) 0.1060.01 0.1360.01 P = 0.087
Data are mean 6 SEM.
doi:10.1371/journal.pone.0072449.t003
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quently analyzed for total cholesterol, HDL-cholesterol, LDL-
cholesterol, triacylglycerol (enzymatic methods, automated ana-
lyser), insulin (chemiluminescent microparticle immunoassay) and
HbA1c (boronate-affinity HPLC) (all conducted according to
clinical diagnostic standards by Alfred Hospital Pathology). For the
animal studies, plasma measurements were performed on blood
collected from the tail vein and centrifuged at 6000 rpm for
10 min at 4uC. Insulin was measured by ELISA (Linco Research,
St. Louis, MO, USA). Plasma non-esterified fatty acids (NEFA)
were determined using a colorimetric kit (Wako Pure Chemical
Industries, Osaka, Japan). Free plasma glycerol levels were
determined using a commercially available kit (Sigma Aldrich,
St. Louis, MO, USA). Plasma S1P was measured with a
commercially available competitive ELISA designed for plasma/
serum determination of S1P concentration (Echelon, Salt Lake
City, UT). The S1P ELISA measures total S1P concentrations in
plasma/serum without distinction between lipoprotein/albumin
bound S1P fractions.
Statistical Analysis
Data are reported as mean 6 SEM. Comparisons between data
from two groups were made using students two-tailed un-paired or
paired (fed/fasting experiments) t-tests. Associations between
variables were investigated using Spearman correlation coefficient
with GraphPad Prism software. Statistical significance was
accepted at P,0.05.
Results
Plasma S1P is Elevated in Mouse Models of Obesity and
Insulin Resistance
To determine if circulating S1P levels are altered in obesity and
insulin resistance, we studied two commonly used mouse models of
obesity and insulin resistance; the chronically HFD fed and
genetically obese chow fed ob/ob mouse. The metabolic charac-
teristics of these models are presented in Table 1 and 2. As
expected, mice maintained on the HFD displayed key metabolic
disturbances associated with obesity such as fasting hyperglycae-
mia, hyperinsulinaemia, and elevated plasma triglycerides
(Table 1). Similarly, the ob/ob mice displayed severe obesity and
fasting hyperglycaemia when compared with their lean counter-
parts (Table 2). Despite the differences in the aetiology of obesity
in these mouse models (i.e. one consumes excess fat and sugar
calories while the other over-eats a standard laboratory chow diet),
both HFD induced and genetically obese ob/ob mice had
significantly elevated plasma S1P concentrations (Fig. 1A & B).
Plasma S1P is Elevated in Obese Humans and Correlates
Positively with Indices of Metabolic Dysfunction
To determine whether our findings of elevated plasma S1P
concentrations in obese mice were also conserved in humans, we
measured the plasma S1P levels in a cohort of well characterised
obese (with characteristics of the metabolic syndrome) and lean
control subjects. The clinical characteristics of the human subjects
are presented in Table 3. Subjects did not differ in age and height
and were completely un-medicated. Body mass, BMI, body fat
percentage and waist circumference were higher in the obese
subjects. While fasting blood glucose levels were normal in the
obese individuals, fasting plasma insulin levels and HOMA-IR
were elevated compared to the control subjects. Furthermore,
obese subjects had significantly higher blood glucose levels at 60
and 120 min during the OGTT, indicating the presence of glucose
intolerance and insulin resistance. In relation to plasma lipids, the
obese subjects had significantly higher plasma triglycerides and
NEFAs and significantly lower HDL cholesterol while there was a
non-significant trend for LDL cholesterol (P = 0.059) to be higher
in the obese subjects. Consistent with our finding in the rodent
models of obesity, plasma S1P levels were also higher (,28%;
P,0.01) in the obese subjects when compared with the lean
controls (Fig. 1C). Next, we performed correlation analysis to
examine if a relationship exists between the plasma S1P levels and
any clinical indices of the metabolic syndrome. Plasma S1P levels
were positively correlated with body fat percentage (Fig. 2A), BMI
(Fig. 2B), waist circumference (Fig. 2C), fasting plasma insulin
(Fig. 2D), HOMA-IR (Fig. 2E), HbA1c (Fig. 2F), total and LDL
cholesterol (Fig. 2G & H). Interestingly, we were unable to detect
any correlation between plasma S1P levels and HDL cholesterol,
NEFAs, triglycerides or glycerol (data not shown).
Plasma S1P is Increased with Fasting in Mice
Given obesity is associated with increased lipid flux and plasma
S1P was elevated in obesity, we next investigated whether an acute
fast which increases lipid flux, would also alter plasma S1P
concentrations. Plasma S1P levels were measured in both the fed
and fasted conditions. Compared to the fed condition, fasting
(12 h) resulted in a significant loss of bodyweight (5.5% of starting
bodyweight; Fig. 3A) which was paralleled by a significant increase
in plasma NEFA levels (Fig. 3B). Interestingly, there was a robust
Figure 1. Plasma S1P concentrations are elevated in obesity. Plasma S1P concentrations in chow (N= 13) and HFD (N=14) fed mice (A);
plasma S1P levels in lean (N= 6) and ob/ob (N = 8) mice (B) and circulating S1P in lean (N= 15) and obese (N= 10) humans (C). Data are mean 6 SEM.
**P,0.01.
doi:10.1371/journal.pone.0072449.g001
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increase (,60%) in plasma S1P concentration with fasting
(Fig. 3C).
Discussion
Traditionally dyslipidaemia has been characterized by an
elevation in plasma triglycerides, total cholesterol and reduction
in HDL cholesterol. However, it is becoming increasingly evident
that obesity and type 2 diabetes mellitus are characterized by
alterations in other circulating lipid species including the bioactive
sphingolipid ceramide [4,8,14]. Such bioactive lipids may play a
more causal mechanistic role in the development of insulin
resistance along with other associated complications such as
atherosclerosis [8–12]. Here we extend those findings by
demonstrating that another sphingolipid metabolite, S1P, is
significantly elevated in the plasma of obese mice and humans.
Furthermore, plasma S1P concentrations in humans positively
correlate with clinical indices of metabolic and cardiovascular
dysfunction including fasting insulin, HOMA-IR, HbA1c, total
and LDL cholesterol, BMI, waist circumference and body fat
percentage. We also report that plasma S1P levels in normal
healthy mice are robustly increased under acute fasting conditions.
Thus it seems that circulating S1P levels are sensitive to changes in
metabolic status. Indeed, it is possible that increased lipid flux
and/or availability (NEFAs, triglycerides, cholesterol) which are
associated with obesity and insulin resistance may govern the
production and ultimately the rise in plasma S1P.
It has previously been shown that plasma S1P levels are
increased in the genetically obese ob/ob mouse [12]. Here we
extend upon these findings by showing that in addition to the
obese ob/ob mouse model, plasma S1P is also increased in HFD
fed obese mice and more importantly in obese humans.
Furthermore, S1P is positively correlated with clinical indices of
the metabolic syndrome. However, whether S1P is simply a
biomarker of the metabolic syndrome or whether it plays a
mechanistic role in the development of obesity related pathologies
such as insulin resistance is not known. This is challenging to
resolve especially given the complex and sometimes paradoxical
roles S1P plays in mammalian biology [13,20,25]. In the context
of the metabolic syndrome and cardiovascular disease, S1P has
been shown to have pro-survival (anti-apoptotic) [26] and anti-
inflammatory actions on hepatocytes [27], kidney podocytes [28],
protective actions on the cardiovascular system [29], including
improvements in blood flow recovery following ischemia [30], and
has been implicated in the metabolically protective actions of
adiponectin [31]. S1P has also been shown to have anti-
inflammatory actions on macrophages [32]. This may be
particularly relevant as obesity is characterized by chronic low-
grade adipose tissue inflammation, thought to be predominantly
mediated by macrophages that infiltrate obese adipose tissue
which secrete pro-inflammatory cytokines [33]. However, in
contrast to these findings in macrophages, treatment of adipocytes
with S1P has been shown to have pro-inflammatory/pro-
thrombotic actions, leading to increased gene expression of
plasminogen activator inhibitor-1, TNF-a, interleukin-6, and
keratinocyte-derived chemokine [12], thus adding further com-
plexity to its role in obesity and metabolic dysfunction. While S1P
has been shown to have many protective actions that improve cell
survival under pathological stress settings, these same actions,
particularly those related to its effects on anti-apoptotic pathways
and angiogenesis have however strongly implicated S1P in the
development of cancer [34]. Given obesity is associated with
increased prevalence of certain cancers [35], it is therefore difficult
to ascertain whether the increase in S1P would be beneficial or
detrimental in the setting of obesity. Nonetheless, future research
should focus on large population studies to determine if there is a
relationship between the incidence of cancer and high circulating
S1P concentrations.
The findings of our study show that circulating S1P is elevated
in obesity, however, we can only speculate regarding the
mechanisms. Recently, studies in mice have shown that S1P
regulates glucose stimulated insulin secretion in pancreatic b-cells
[36], while its clinically approved therapeutic analogue FTY720
(Fingolimod), which is a S1P receptor agonist, normalizes blood
glucose levels in type 2 diabetic db/db mice by increasing b-cell
mass and circulating insulin levels [37]. S1P has also been shown
to increase basal glucose uptake in C2C12 muscle cells [22],
however, the consequences of increased plasma S1P on in vivo
glucose metabolism are not known and whether S1P affects
insulin-stimulated glucose uptake is not clear. In addition, our own
recent work has shown that FTY720 treatment reduced muscle
ceramide, diacylglycerol and triglyceride levels in HFD induced
obese mice, ultimately leading to improved whole body glucose
homeostasis [38]. In support of the potentially protective role of
Figure 2. Plasma S1P concentrations correlate with clinical indices of metabolic dysfunction in humans. Plasma S1P concentrations
correlate with percent body fat (A), BMI (B), waist circumference (C), fasting plasma insulin (D), HOMA-IR (E), HbA1c (F), total (G) and LDL (H)
cholesterol.
doi:10.1371/journal.pone.0072449.g002
Figure 3. Plasma S1P concentrations in mice are elevated in response to fasting. Changes in body mass (A), blood glucose (B), plasma
NEFA (C) and plasma S1P concentrations (D) in response to fasting. Data are mean 6 SEM. *P,0.05; **P,0.01, N = 11–12.
doi:10.1371/journal.pone.0072449.g003
S1P in Obesity
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S1P in obesity, endurance trained humans, who are remarkably
insulin sensitive [39,40], have been shown to have ,40% higher
plasma S1P concentrations than untrained controls [41]. Similar-
ly, one single exercise bout in untrained human subjects, which is a
physiological situation that is accompanied by a simultaneous
increase in lipid flux [42] (ie. adipose tissue lipolysis, skeletal
muscle lipid uptake and oxidation) and insulin sensitivity [43],
increases plasma S1P levels by ,42%, an effect that is
accompanied by decreased erythrocyte ceramide levels [41]. This
is somewhat similar to our fasting experiment in mice, which like
exercise, would be expected to improve insulin sensitivity while
also increasing lipid flux [44], resulting in a significant rise in
plasma S1P levels (Fig. 3D). Thus it is plausible that an increase in
lipid flux which is evident by elevated rates of lipolysis and NEFA
release into the circulation, as seen in obesity [45], type 2 diabetes
[46], exercise [42] and fasting [47] may result in increased S1P
synthesis and secretion into the plasma. In relation to fasting
however, previous research in humans has shown that a 10 h
overnight fast did not result in altered S1P concentrations when
compared to the fed state [48]. This may possibly be explained by
the difference in the relative severity of the fast in mice compared
to humans. For example, a 10 h fast in humans has relatively
minor effects on hepatic glycogen content [49,50], while in mice, a
12 h fast results in almost complete depletion of hepatic glycogen
[44]. Based on the collective results of the abovementioned studies,
we speculate that S1P may elicit potentially protective effects by
promoting pancreatic b-cell regeneration/survival during the
forced compensatory hyperinsulinaemia that is required to
maintain euglycaemia in an insulin resistant obese state.
Additionally, based on the fact that we have previously shown
that the S1P analogue FTY720 prevents muscle lipid accumula-
tion in HFD mice [38], it is possible that elevated plasma S1P may
play a role in trying to minimise excessive bioactive lipid build-up
in tissues such as liver, pancreatic b-cells and skeletal muscle, an
effect most likely mediated by its ability to signal via the S1P
receptors [38]. Although the origin of triacylglycerol and
diacylglycerol is distinct to that of ceramide, it suggests that
alterations in sphingolipid metabolism can have pronounced
effects on numerous lipid classes, including those not directly
linked to ceramide. Clearly more work is required to further
elucidate the biological role of circulating S1P, particularly in the
regulation of pancreatic b-cell function and energy metabolism.
While it is well known that the majority (,54%) of the plasma
S1P pool is bound to HDL cholesterol [17,19], we did not find an
association between plasma S1P levels and the total HDL
cholesterol fraction (r =20.128, P = 0.54). In support of this lack
of a correlation with HDL, recent studies by Hammad and
colleagues have shown that S1P transport in lipoproteins was not
limited by the concentration of HDL cholesterol in individual
subjects due to the high variability of S1P content in HDL
particles [17]. Additionally, the relative ‘per particle’ S1P content
was actually highest in the larger VLDL particles [48], thus
possibly explaining our positive correlations between plasma S1P
with total and LDL but not HDL cholesterol (Fig. 2G & H). It is
also worth noting that some of the cardio-protective functions of
HDL have been attributed to its high S1P content [51]. The S1P
cargo on HDL particles may be cardio-protective due to its cell
survival actions on cardiomyocytes and effects on the vascular
endothelium that enhance blood flow/angiogenesis [51,52].
The source of the increased S1P levels in obesity is unclear and
requires further investigation. Given the bulk of the circulating
S1P pool comes from erythrocytes, leukocytes and vascular
endothelial cells [16,18], there is a distinct possibility that these
cells may also be over-secreting this molecule in obesity. However,
the possibility remains that the source could be other cells that are
more directly affected by obesity such as adipocytes and/or
hepatocytes, although it has been reported that hepatocytes do not
secrete S1P, and that hepatic derived S1P is of endothelial origin
[18]. Furthermore, the increased plasma S1P levels seen in obesity
could also potentially result from decreased cellular/tissue S1P
degradation by the cleavage enzyme S1P lyase. If this was to be
the case, decreased S1P clearance rather than increased secretion
could be the reason circulating S1P is increased in obesity.
In conclusion, we demonstrate that plasma S1P is elevated in
obese humans and is positively correlated with clinical features of
metabolic dysfunction, particularly fasting insulin, HOMA-IR,
HbA1c, total and LDL cholesterol, BMI, waist circumference and
body fat percentage. Furthermore, circulating S1P is also elevated
in HFD induced and genetically obese ob/ob mice. Additionally,
we also show that an acute period of fasting (12 h) in mice robustly
increases plasma S1P levels. Collectively these results show that
plasma S1P concentrations are altered in association with
metabolic status, possibly via an increase in lipid flux and/or
availability. Future research should focus on determining the role
that circulating S1P may have on nutrient metabolism and
whether it contributes to or alleviates metabolic abnormalities such
as insulin resistance and defective glucose homoeostasis.
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